cAMP signalling in trypanosomatids: role in pathogenesis and as a drug target

Trends Parasitol. 2015 Aug;31(8):373-9. doi: 10.1016/j.pt.2015.04.014. Epub 2015 May 21.

Abstract

Despite recent research linking cAMP signalling to virulence in trypanosomatids and detailed studies of trypanosomatid adenylyl cyclases (ACs) and phosphodiesterases (PDEs) since their discoveries 40 years ago, downstream components of the pathway and their biological functions have remained remarkably elusive. However, in recent years, significant discoveries have been made: a role for parasite ACs has been proposed in cytokinesis, evasion of the host immune response, and social motility. cAMP phosphodiesterases PDEB1 and PDEB2 were found to be essential for survival and virulence of Trypanosoma brucei and, in Trypanosoma cruzi, PDEC2 was shown to be required for normal osmoregulation. As we discuss here, these breakthroughs have led to an ongoing surge in the development of PDE inhibitors as lead compounds for trypanocidal drugs.

Keywords: adenylyl cyclases; cAMP; drug target; phosphodiesterases; trypanosomatids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Cyclic AMP / metabolism*
  • Drug Discovery
  • Euglenozoa Infections / parasitology
  • Host-Parasite Interactions
  • Humans
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphoric Diester Hydrolases / metabolism
  • Signal Transduction*
  • Trypanocidal Agents / pharmacology
  • Trypanosomatina / drug effects
  • Trypanosomatina / enzymology
  • Trypanosomatina / pathogenicity*
  • Trypanosomatina / physiology*

Substances

  • Phosphodiesterase Inhibitors
  • Trypanocidal Agents
  • Cyclic AMP
  • Phosphoric Diester Hydrolases
  • Adenylyl Cyclases